HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
Discovering New Therapeutics Uses for Existing Molecules

New Therapeutic Uses Funding Information

NIH-Industry Partnerships

NIH launched the NIH-Industry Partnerships initiative in May 2012 as part of the Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses) program. By pairing researchers with a selection of pharmaceutical industry assets, this innovative program aims to test ideas for new therapeutic uses, ultimately identifying promising new treatments for patients.

Bench-to-Clinic Repurposing

In August 2016, NCATS announced a funding opportunity to explore a potential new use of an existing experimental drug or biologic as well as Food and Drug Administration-approved therapies already on the market. Through the Bench-to-Clinic Repurposing initiative, NCATS will support pre-clinical studies to test the utility of an independent crowdsourcing effort, computational algorithm or big dataset from patient records to predict new uses of a drug or biologic.

Current Opportunities

NCATS has released the following funding opportunity announcements:

Technical Assistance Slides for NIH-Industry Partnerships (PDF -387KB)

Expired Announcements

These expired funding announcements include details on the application process, eligibility and timelines for the program:

  • RFA-TR-17-001: Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (X02)
  • RFA-TR-16-015: Bench Testing Therapeutic/Indication Pairing Strategies (UH2/UH3)
  • PA-16-183: Limited Competition: Rare Diseases Clinical Research Network (RDCRN) Project Supplements for Clinical Trials to Repurpose Drugs in Collaboration with E-Rare Awardees (Admin Supp)
  • RFA-TR-16-001: Pre-clinical Research Based on Existing Repurposing Tools (R21)
  • NOT-TR-15-008: Notice of Clarification Regarding Clinical Trial Documentation Requirements for New Therapeutic Uses Investigators
  • PAR-14-210: Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3)
  • PAR-14-211: Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH3)
  • PAR-14-212: Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH2/UH3)
  • PAR-14-213: Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (X02)
  • NOT-TR-14-001: Notice to Solicit Compounds for Inclusion in the NIH-Industry New Therapeutic Uses Program
  • NOT-TR-12-010: Technical Assistance Webinar for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules Limited Competition RFA-TR-12-004 (UH2/UH3) and RFA-TR-12-005 (UH3)
  • NOT-TR-12-008: Clarification for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules PAR-12-203 (X02) Pre-Application, and Limited Competition RFA-TR-12-004 (UH2/UH3) and RFA-TR-12-005 (UH3)
  • PAR-12-203: A Pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules (X02)
  • RFA-TR-12-004: Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules (UH2/UH3)
  • RFA-TR-12-005: Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules (UH3)
Last updated: 09-06-2017
▲ Back to top